Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peking Univ. GPX4 compound 8e: sourced facts only. name: "Hence, 8e was discovered as a potent and highly efficacious GPX4 degrader based upon the inhibitor RSL3." [PMID:36603510]; target: "Hence, 8e was discovered as a potent and highly efficacious GPX4 degrader based upon the inhibitor RSL3." [PMID:36603510]; developer: "Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University, Beijing, China. Electronic address: [email protected]." [PMID:36603510]; modality: "we designed and synthesized a series of GPX4 degraders using PROTAC technology in terms of its excellent characteristics such as high efficiency and selectivity and the capacity of overcoming resistance." [PMID:36603510]; stage: "Our data also suggested that 8e and RSL3 could potently induce ferroptosis of HT1080 cells via GPX4 inhibition and degradation." [PMID:36603510]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Peking Univ. GPX4 compound 8e.